Texas Prostate Completes 100th TULSA Procedure, Revolutionizing Cancer Care

A Texas-based urology practice has reached a major milestone in prostate treatment. Texas Prostate, led by Dr. James Cochran, recently completed its 100th TULSA Procedure at Dallas Medical Center. The advanced therapy uses MRI guidance and robotically controlled ultrasound to treat prostate cancer and benign prostatic hyperplasia (BPH) without incisions.

The clinic's shift to a Medicare-supported model has driven rapid growth, with procedure numbers rising by 500%.

The TULSA Procedure relies on the TULSA-PRO system, developed by Profound Medical Corp., a commercial-stage medical device company. This technology combines MRI imaging with robotically controlled directional ultrasound to ablate diseased prostate tissue. Real-time MRI thermography allows doctors to monitor and automatically adjust temperatures during treatment, improving both precision and safety.

Dr. Cochran previously focused on focal HIFU procedures but now primarily offers TULSA due to its broader applications and enhanced safety profile. The method treats a wider range of prostate diseases while reducing risks compared to older techniques. Texas Prostate's collaboration with Dallas Medical Center enabled a transition to Medicare coverage, making the procedure more accessible. This change has significantly increased patient numbers, with a 500% rise in TULSA Procedures performed. Profound Medical also markets Sonalleve, another MRI-guided therapy, for pain relief in bone metastases, gynaecologic conditions, and uterine fibroids. The company's platforms aim to provide incision-free, personalised treatments across multiple medical fields.

The 100th TULSA Procedure at Texas Prostate marks a key step in expanding access to MRI-guided prostate therapy. With Medicare support and growing adoption, more patients now benefit from this incision-free treatment. The technology's precision and safety continue to drive its use in urology practices.